ROSUVASTATIN CALCIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rosuvastatin Calcium, and what generic alternatives are available?
Rosuvastatin Calcium is a drug marketed by Accord Hlthcare, Alkem Labs Ltd, Amneal Pharms Co, Apotex, Aurobindo Pharma Ltd, Biocon Pharma, Cadila Pharms Ltd, Changzhou Pharm, Chartwell Rx, Glenmark Pharms, Hetero Labs Ltd V, Inventia, Lupin, MSN, Renata, Sandoz, Sciegen Pharms Inc, Shandong, Strides Pharma, Sun Pharm, Sunshine, Teva Pharms Usa, Torrent, Umedica, Watson Labs Inc, Zhejiang Jingxin, and Zhejiang Yongtai. and is included in twenty-seven NDAs.
The generic ingredient in ROSUVASTATIN CALCIUM is rosuvastatin calcium. There are forty-two drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the rosuvastatin calcium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rosuvastatin Calcium
A generic version of ROSUVASTATIN CALCIUM was approved as rosuvastatin calcium by WATSON LABS INC on April 29th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ROSUVASTATIN CALCIUM?
- What are the global sales for ROSUVASTATIN CALCIUM?
- What is Average Wholesale Price for ROSUVASTATIN CALCIUM?
Summary for ROSUVASTATIN CALCIUM
![ROSUVASTATIN CALCIUM drug patent expirations Drug patent expirations by year for ROSUVASTATIN CALCIUM](/p/graph/s/t/ROSUVASTATIN_CALCIUM-patent-expirations.png)
![Drug Prices for ROSUVASTATIN CALCIUM](/p/graph/drug-price/ROSUVASTATIN+CALCIUM.png)
See drug prices for ROSUVASTATIN CALCIUM
![Drug Sales Revenue Trends for ROSUVASTATIN CALCIUM](/p/graph/drug-sales-revenues/ROSUVASTATIN+CALCIUM.png)
Recent Clinical Trials for ROSUVASTATIN CALCIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Pharma Medica Research, Inc. | Phase 1 |
NewAmsterdam Pharma | Phase 1 |
Samsung Medical Center | Phase 4 |
Pharmacology for ROSUVASTATIN CALCIUM
Drug Class | HMG-CoA Reductase Inhibitor |
Mechanism of Action | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Medical Subject Heading (MeSH) Categories for ROSUVASTATIN CALCIUM
Anatomical Therapeutic Chemical (ATC) Classes for ROSUVASTATIN CALCIUM
Paragraph IV (Patent) Challenges for ROSUVASTATIN CALCIUM
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CRESTOR | Tablets | rosuvastatin calcium | 5 mg, 10 mg, 20 mg and 40 mg | 021366 | 9 | 2007-08-13 |
US Patents and Regulatory Information for ROSUVASTATIN CALCIUM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shandong | ROSUVASTATIN CALCIUM | rosuvastatin calcium | TABLET;ORAL | 207375-004 | May 7, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Zhejiang Jingxin | ROSUVASTATIN CALCIUM | rosuvastatin calcium | TABLET;ORAL | 206513-001 | Mar 1, 2019 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Hetero Labs Ltd V | ROSUVASTATIN CALCIUM | rosuvastatin calcium | TABLET;ORAL | 207616-001 | Oct 31, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Changzhou Pharm | ROSUVASTATIN CALCIUM | rosuvastatin calcium | TABLET;ORAL | 207408-004 | Oct 31, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |